Compare · GILD vs GLUE
GILD vs GLUE
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and GLUE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.88B, about 102.2x GLUE ($1.58B).
- Over the past year, GILD is up 22.6% and GLUE is up 301.4% - GLUE leads by 278.8 points.
- GILD has been more active in the news (8 items in the past 4 weeks vs 6 for GLUE).
- GILD has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- Gilead Sciences Inc.
- Monte Rosa Therapeutics Inc.
- Price
- $130.38-2.48%
- $19.79-1.98%
- Market cap
- $161.88B
- $1.58B
- 1M return
- -5.67%
- +26.05%
- 1Y return
- +22.62%
- +301.42%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick
Latest GLUE
- Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
- SEC Form 144 filed by Monte Rosa Therapeutics Inc.
- SEC Form 4 filed by Warmuth Markus
- SEC Form 4 filed by Nickson Philip
- SEC Form 4 filed by Bowen Matthew
- SEC Form 3 filed by new insider Bowen Matthew
- Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.
- SEC Form S-8 filed by Monte Rosa Therapeutics Inc.
- SEC Form 10-K filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits